Recent Updates
Recently added Catalysts
TVTX

Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

Key Takeaway: SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 4:00 p.m. PT. A live we
Price reaction · baseline $25.73 (2022-05-02 close) · hit after-hours · 2 other TVTX headline(s) in the window, move may be shared
day 0 close · peak
-0.2%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+79%
120-day peak, hindsight
Typical move
4.7%
average across 9 past catalysts
Lead asset
sparsentan
Phase 3 · Immunoglobulin A Nephropathy

Full Press Release Details

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 4:00 p.m. PT.
A live webcast will be available at https://ir.travere.com/events-presentations and an archived replay will be accessible for up to 30 days.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com
Last updated: May 3, 2022